Skip to content

All Episodes – Page 6

Browse our complete library of interviews and discussions with leading experts in oncology.

Yasmin Civil MD PhD: Low-Risk ER+ Breast Cancer: ABLATIVE Trial Finds Marked Benefit from MRI-Guided Single-Dose Neoadjuvant Partial Breast Radiotherapy

Yasmin Civil MD PhD: Low-Risk ER+ Breast Cancer: ABLATIVE Trial Finds Marked Benefit from MRI-Guided Single-Dose Neoadjuvant Partial Breast Radiotherapy

Partial breast irradiation, given before breast-conserving surgery, achieved durable pathologic complete remissions in low-risk breast cancer, and even held out the prospect of surgery-free treatment

8 September 2025
9 min
Érica A. Oliveira PhD: How to Overcome Drug Resistance: Patient Derived Organoids Study Finds Epigenetic Pathways in Colorectal Cancer

Érica A. Oliveira PhD: How to Overcome Drug Resistance: Patient Derived Organoids Study Finds Epigenetic Pathways in Colorectal Cancer

Patient Derived Organoids Shine a Light on Epigenetic Archetypes as Key Drivers of Cancer Drug Resistance LONDON, UK—How to stay ahead with treatment as cancer cells evolve to evade therapies and regi

22 August 2025
25 min
Rebecca Dent MD: First-Line T-DXd Combination Adds More Than a Year of Progression Free Survival for Patients with Advanced HER2 Positive Breast Cancer

Rebecca Dent MD: First-Line T-DXd Combination Adds More Than a Year of Progression Free Survival for Patients with Advanced HER2 Positive Breast Cancer

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+

25 July 2025
Erica L. Mayer MD MPH: Adjuvant Abemaciclib: Start Low, then Dose Escalate in Early-stage HR+/HER2- Breast Cancer: TRADE Study Findings

Erica L. Mayer MD MPH: Adjuvant Abemaciclib: Start Low, then Dose Escalate in Early-stage HR+/HER2- Breast Cancer: TRADE Study Findings

Interview with Erica L. Mayer MD MPH, Director of Breast Cancer Clinical Research, Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA. With comment from: Pat Price MD, Imperial College

18 July 2025
9 min
Patients with Early-Stage Non-Squamous Non-Small Cell Lung Cancer Who can Benefit from Adjuvant Chemotherapy

Patients with Early-Stage Non-Squamous Non-Small Cell Lung Cancer Who can Benefit from Adjuvant Chemotherapy

An interview with: David R Spigel FASCO, MD, Chief Scientific Officer, Sarah Cannon Research Institute, Nashville, Tennessee, US With comment from: Luis G Paz-Ares MD PhD Chair of Medical Oncology, Ho

12 July 2025
12 min
Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers

Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers

“Adjuvant nivolumab added to chemoradiotherapy after surgery provided a statistically and clinically meaningful disease-free survival improvement in PD-L1 all-comers patients. This is the first time i

3 July 2025
10 min
Yelena Janjigian ASCO Plenary: Peri-Operative Chemo-Immunotherapy Delays Recurrence in Patients with Gastric or GE Junction Cancers

Yelena Janjigian ASCO Plenary: Peri-Operative Chemo-Immunotherapy Delays Recurrence in Patients with Gastric or GE Junction Cancers

Yelena Y. Janjigian MD says that perioperative anti-PD-L1 immunotherapy with durvalumab was a “game changer” meriting use as a new standard of care when used together with chemotherapy to

17 June 2025
5 min
Christopher Booth MD: Post-Surgery Exercise Therapy Reduced Recurrence Risk and Extended Life in Patients with Colon Cancer

Christopher Booth MD: Post-Surgery Exercise Therapy Reduced Recurrence Risk and Extended Life in Patients with Colon Cancer

Exercise was as good as the addition of a drug among patients with high risk stage 2 or stage 3 colon cancer after curative surgery, extending life and preventing cancer recurrence. Christopher Booth

12 June 2025
11 min